Olon has recently announced the acquisition of HuvePharma Italia Srl and its Garessio plant. Could you start by telling us what the primary objective of this acquisition is?
The main goal of acquiring HuvePharma Italia Srl is to significantly boost our overall production capacity, particularly in the development and production of active pharmaceutical ingredients (APIs). By integrating the Garessio plant into our network, we plan to revive and fully leverage its production potential, which aligns with our broader strategy of expanding our footprint in the global API market.

How does this acquisition align with Olon’s broader growth and expansion strategy?
Since its inception, Olon has pursued a consistent strategy of growth, consolidation, and expansion, both organically and through strategic acquisitions. The expertise of the companies we acquire, like HuvePharma Italia, enriches our offerings and enhances our competitiveness. This acquisition is a perfect example of that approach—by expanding our production capacity, we’re reinforcing our presence in key markets and advancing our long-term business ob ...